Abstract
Acute mesenteric ischemia (AMI) is a rare condition that may be associated with a variety of congenital prothrombotic disorders (PDs). The purpose of this study was to assess the prevalence of these disorders in 28 AMI patients compared with 103 healthy individuals from the northeastern region of Turkey. They were screened for protein C, antithrombin III, and protein S deficiencies; and gene analysis was performed using the polymerase chain reaction. A PD was revealed in 16 (57%) patients and 33 (32%) controls (p = 0.020). Factor V Leiden (FVL), prothrombin G20210A mutation, and TT677 homozygous mutation of methylenetetrahydrofolate reductase was detected in 10 (36%) patients versus 16 (15%) controls (p = 0.035), 3 (11%) patients versus 10 (9%) controls (p = 1.00), and 1 (3%) patient versus no controls, respectively. Consistent with caucasian ethnic groups, there was high prevalence of PDs, especially FVL; and these abnormalities might be a significant predisposing factor in the pathogenesis of AMI.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Markis M, Rosendaal FR, Preston FE. Familial thrombophilia: genetic risk and management. J. Intern. Med. Suppl. 1997;740:9–15
Margaglione M, D’Andrea G, d’Addedda M, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb. Haemost. 1998;79:907–911
AğaoğLu N, Türkyılmaz S, Arslan MK. Prothrombotic disorders in patients with mesenteric vein thrombosis. J. Invest. Surg. 2003;16:299–304
Gurgey A, Haznedaroğlu IC, Agesel T, et al. Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkisk patients with thrombosis. Am. J. Hematol. 2001;67:107–111
Akar N, Akar E, Dalgin G, et al. Frequency of factor V 1691 G-A mutation in Turkish population. Thromb. Haemost. 1997;78:1527–1529
Akar N, Misirlioğlu M, Akar E, et al. Prothrombin gene 20210 G: a mutation in Turkish population. Am. J. Hematol. 1998;58:249
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure of extracting DNA from human nucleated cells. Nucleic Acids Res 1998;16:1215
Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin. Hematol. 1997;34:171–187
Shen MC, Lin JS, Tsay W. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb.Res.1997;87:377–385
Lin JS, Shen NC, Tsay W. The mutation at position 20210 in the 3′-untranslated region of the prothrombin gone is extremely rare in Taiwanese Chinese patients with venous thrombophilia. Thromb. Haemost. 1998;80:343
Rees DC, Cox M, Clegg JB. World distribution of FV Leiden. Lancet 1995;346:1133–1134
Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of FV Leiden in 4047 men and women. J.A.M.A. 1997;277:1305–1130
Cattaneo M, Chantatangkul V, Taioli E. The G20210: a mutation of the prothrombin gene in patients with previous first episodes of deep vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase TT677 and plasma prothrombin levels. Thromb. Res. 1999;93:1–8
Gómez RR, Cuesta M, García M. Prevalence of the FV Leiden mutation in the Spanish population [abstract] Thromb. Haemost. 1997;77:224
Rosendaal FR, Doggen CJ, Zivelin A. Geographic distribution of the 20210 G to A prothrombin variant. Thromb. Haemost. 1998;79:706–708
Souto JC, Coll I, Llobe D, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb. Haemost. 1998;80:306–309
Genoud V, Castrion M, Annichino-Bizzacchi J, et al. Prevalence of three prothrombotic polymorphisms factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase (MTHFR) C 677T in Argentina. Thromb. Res. 2000;100:127–131
Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in U.S. physicians. Circulation 1996;94:2410–2416
Jacques PF, Bostom AG, William RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;3:7–9
Maurizio M, Giovanna DA, Marina DA, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the factor V Leiden and the prothrombin A20210 mutation. Thromb. Haemost. 1998;79:907–911
Rintelen C, Pabinger I, Leckner K, et al. No evidence for an increase of the risk of venous thrombosis in patients with factor V Leiden by the homozygous mutation in the methylenetetrahydrofolate gene. Blood Coagul Fibrinolysis 1999;10: 101–105
Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032–2036
Motti C, Gnasso A, Bernardini S. Common mutation of methylenetetrahydrofolate reductase; correlation with homocysteine and other risk factors for vascular disease. Atherosclerosis 1998;139:377–383
Camacho Vanegas O, Giusti B, Restropo Fernandez CM, et al. Frequency of factor V (FV) Leiden and C677T methylenetetrahydrofolate reductase (MTHFR) mutations in Colombians. Thromb. Haemost. 1998;79:883–884
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ağaoğlu, N., Türkyılmaz, S., Ovalı, E. et al. Prevalence of Prothrombotic Abnormalities in Patients with Acute Mesenteric Ischemia. World J. Surg. 29, 1135–1138 (2005). https://doi.org/10.1007/s00268-005-7692-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-005-7692-5